share_log

HC Wainwright & Co. Reiterates Buy on UroGen Pharma, Maintains $54 Price Target

HC Wainwright & Co. Reiterates Buy on UroGen Pharma, Maintains $54 Price Target

HC Wainwright & Co.重申对UroGen Pharma的买入,维持54美元的目标股价
Benzinga ·  2023/10/04 06:16

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates UroGen Pharma (NASDAQ:URGN) with a Buy and maintains $54 price target.

HC Wainwright&Co.分析师Raghuram Selvaraju重申UroGen Pharma(纳斯达克:URGN)将买入,并维持54美元的目标价。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发